+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
MALE
ID06387056

Safety and Effectiveness of Genomic Biomarker-Guided Neoadjuvant Treatments for Advanced and Oligometastatic Prostate Cancer

Led by The First Affiliated Hospital of Xiamen University · Updated on 2024-04-26

40

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of neoadjuvant therapy guided by genomic biomarkers for men with locally advanced and oligometastatic prostate cancer. This phase 2 study aims to tailor treatment based on each patients tumor genetic profile to better understand how these therapies work before surgery. Participants will be assigned to one of four treatment groups based on their genomic profile. Each group receives a combination of rezvilutamide, androgen deprivation therapy ADT, and one additional drug docetaxel, pamiparib, cisplatin, or tislelizumab. Treatments are given over about 24 weeks, followed by imaging to assess response and then radical prostatectomy plus pelvic lymph node dissection. The study will also analyze tissue and survival outcomes after surgery. During the study, participants will undergo genetic testing, imaging scans including PSMA PETCT, and various laboratory tests. Researchers will monitor clinical and pathological responses at 20 and 24 weeks, including rates of complete response and minimal residual disease. Longer-term follow-up will assess progression-free and overall survival for up to three years. Safety and tolerability will be closely observed throughout the treatment and surgery periods.

CONDITIONS

Brief Title

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Research Team

K

Kaiyan Zhang, M.D.

H

Haichao Huang, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here